Ignite Creation Date:
2025-12-25 @ 1:26 AM
Ignite Modification Date:
2025-12-27 @ 11:11 PM
Study NCT ID:
NCT05371093
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-10-15
First Post:
2022-05-09
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma
Sponsor:
Kite, A Gilead Company
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-09-22
Start Date Type:
ACTUAL
Primary Completion Date:
2030-10
Primary Completion Date Type:
ESTIMATED
Completion Date:
2030-10
Completion Date Type:
ESTIMATED
First Submit Date:
2022-05-09
First Submit QC Date:
None
Study First Post Date:
2022-05-12
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-10-14
Last Update Post Date:
2025-10-15
Last Update Post Date Type:
ESTIMATED